Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|March 19, 2005
Treatment of chronic hepatitis C in Canadian prison inmatesJohn D Farley, Victor K Wong, Henry V Chung, et al.Therapeutic Advances in Medical Oncology|September 2, 2022
European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directionsNick Pavlakis, Gary Tincknell, Lisi Elizabeth Lim, et al.Oncotarget|July 18, 2020
Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumoursLisi Elizabeth Lim, David L Chan, David Thomas, et al.BMC Infectious Diseases|March 14, 2018
Epidemiologic analysis of respiratory viral infections among Singapore military servicemen in 2016Yuk-Fai Lau, Wee-Hong Victor Koh, Clement Kan, et al.Neurology|October 1, 2013
Deletions in GRID2 lead to a recessive syndrome of cerebellar ataxia and tonic upgaze in humansL Benjamin Hills, Amira Masri, Kotaro Konno, et al.Journal of Neuro-Oncology|July 23, 2026
Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patternsEmma Sanderson, Katharine Drummond, Anthony Dowling, et al.Translational Andrology and Urology|May 10, 2021
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancerEdmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.Pageof 3